SEATTLE, WA--(Marketwire - April 09, 2008) - Targeted Genetics Corporation (NASDAQ: TGEN) today announced the publication of preclinical data characterizing the novel use of Adeno-Associated Viral (AAV) vectors to deliver small interfering RNA (siRNA) for the treatment of Huntington's disease. The goal of this research is to assess the use of interfering RNA to silence the mutant huntingtin gene and thus, reduce the level of the defective protein.
